Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014121416 - TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C

Publication Number WO/2014/121416
Publication Date 14.08.2014
International Application No. PCT/CN2013/000128
International Filing Date 07.02.2013
IPC
C07D 487/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
A61K 31/4985 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 31/4375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4375the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/438
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5025
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
5025ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
Applicants
  • MERCK SHARP & DOHME CORP. [US]/[US] (AllExceptUS)
  • DAI, Xing [CN]/[US] (US)
  • LIU, Hong [CN]/[US] (US)
  • PALANI, Anandan [US]/[US] (US)
  • HE, Shuwen [CN]/[US] (US)
  • BROCKUNIER, Linda L. [US]/[US] (US)
  • NARGUND, Ravi [US]/[US] (US)
  • MARCANTONIO, Karen [US]/[US] (US)
  • ZORN, Nicolas [US]/[US] (US)
  • XIAO, Dong [CN]/[US] (US)
  • PENG, Xuanjia [CN]/[CN] (US)
  • LI, Peng [CN]/[CN] (US)
  • GUO, Tao [CN]/[CN] (US)
Inventors
  • DAI, Xing
  • LIU, Hong
  • PALANI, Anandan
  • HE, Shuwen
  • BROCKUNIER, Linda L.
  • NARGUND, Ravi
  • MARCANTONIO, Karen
  • ZORN, Nicolas
  • XIAO, Dong
  • PENG, Xuanjia
  • LI, Peng
  • GUO, Tao
Agents
  • LIU, SHEN & ASSOCIATES
Priority Data
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C
(FR) COMPOSÉS HÉTÉROCYCLIQUES TÉTRACYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE L'HÉPATITE C
Abstract
(EN) The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
(FR) La présente invention concerne des composés de formule (I) qui sont utiles en tant qu'inhibiteurs de la polymérase NS5B du virus de l'hépatite C (VHC), la synthèse de tels composés, et l'utilisation de tels composés pour l'inhibition de l'activité de la polymérase NS5B du VHC, pour le traitement ou la prévention d'infections à VHC et pour l'inhibition de la réplication virale du VHC et/ou de la production virale de VHC dans un système cellulaire.
Related patent documents
Latest bibliographic data on file with the International Bureau